Liminal BioSciences

Liminal BioSciences, Inc. operates as a clinical stage biopharmaceutical company. The firm focuses on developing distinctive novel small molecule therapeutics for inflammatory, fibrotic, and metabolic diseases using drug discovery platform and a data driven approach. The firm has business operations in Canada and the United Kingdom. Its small molecule product candidate, fezagepras, has completed a Phase 1 multi-ascending dose clinical trial and anticipate conducting a comparative Phase 1a single ascending dose clinical trial to provide comparative data to support development plan. The company was founded on October 14, 1994 and is headquartered in Laval, Canada.

Earnings data Q2 2024

Revenue

Cost of revenue

Gross profit

Operating expenses

SG&A

Other

Operating income

EBITDA

Net income

Earnings per share

Total assets

Current assets

Cash & equivalents

Receivables

Inventory

Non-current assets

Net PPE

Intangibles

Total liabilities

Current liabilities

Short term debt

Income tax payable

Non-current liabilities

Long-term debt

Total equity

Stockholders equity

Minority interest

Total liabilities & equity

Total debt

Net debt

Book value per share

Cash from operations

Funds from operations

Change in working capital

Cash from investing

Capital expenditure

Purchase/sale of investments

Purchase/sale of business

Other sources

Cash from financing

Change in stock

Change in debt

Cash dividends paid

Cash from other sources

Net change in cash

Free cash flow

Liminal BioSciences is a biopharmaceutical corporation supplying state-of-the-art technologies for bio-separations as well as therapeutic products. It specializes in discovering, developing, and commercializing novel small molecule compounds for respiratory, liver, and renal diseases. The company focuses specifically on developing solutions for rare and orphan diseases. Liminal BioSciences was founded in 1992 and is headquartered in Laval, Quebec.

Liminal BioSciences Inc. (LMNL) is technically in oversold territory now, so the heavy selling pressure might have exhausted. This along with strong agreement among Wall Street analysts in raising earnings estimates could lead to a trend reversal for the stock.

After Plunging 34.5% in 4 Weeks, Here's Why the Trend Might Reverse for Liminal BioSciences Inc. (LMNL)

Liminal BioSciences Inc. (LMNL) CEO Bruce Pritchard on Q2 2021 Results - Earnings Call Transcript

Liminal BioSciences Inc. (LMNL) delivered earnings and revenue surprises of 22.73% and -90.24%, respectively, for the quarter ended June 2021. Do the numbers hold clues to what lies ahead for the stock?

Liminal BioSciences Inc. (LMNL) Reports Q2 Loss, Misses Revenue Estimates

Receipt of FDA Approval for Ryplazim® (plasminogen, human-tvmh) Receipt of a Rare Pediatric Disease Priority Review Voucher Signature of Agreement to Divest Plasma-Derived Therapeutics Business to Kedrion Closing of the Sale of Plasma Collection Centers to Kedrion Closing of the Sale of Plasma-Derived Therapeutics Manufacturing Facility to Kedrion Signature of Agreement to Sell Rare Pediatric Disease Priority Review Voucher for US$105M LAVAL, QC and CAMBRIDGE, England, Aug. 16, 2021 /PRNewswire/ - Liminal BioSciences Inc. (Nasdaq: LMNL) ("Liminal BioSciences" or the "Company"), a clinical-stage biopharmaceutical company, today reported its financial results for the second quarter ended June 30, 2021. Liminal BioSciences will host a conference call at 8:30 am (ET) on August 17, 2021.

Liminal BioSciences Reports Second Quarter 2021 Financial Results

The stock price of Liminal BioSciences Inc (NASDAQ: LMNL) increased by over 93% during intraday trading. This is why it happened.

LMNL Stock Price Increases Over 93% Intraday: Why It Happened

Liminal BioSciences Inc's (NASDAQ: LMNL) subsidiary Prometic Biotherapeutics Inc has agreed to sell its Rare Pediatric Disease Priority Review Voucher (PRV) for $105M. The FDA granted the PRV with the approval of Ryplazim (plasminogen, human-tvmh) for plasminogen deficiency type 1 (hypoplasminogenemia).

Liminal BioSciences Stock Is Trading Higher On Sale Of Priority Review Voucher For $105M

LAVAL, QC and CAMBRIDGE, England , Aug. 9, 2021 /PRNewswire/ - Liminal BioSciences Inc. (Nasdaq: LMNL) ("Liminal BioSciences" or the "Company"), announced today that, its subsidiary Prometic Biotherapeutics Inc. ("PBT") has entered into a definitive agreement to sell its Rare Pediatric Disease Priority Review Voucher ("PRV") for USD105M. The PRV was granted by the U.S. Food and Drug Administration ("FDA") with the approval of Ryplazim® (plasminogen, human-tvmh) ("Ryplazim®"), for treatment of patients with plasminogen deficiency type 1 (hypoplasminogenia).

Liminal BioSciences Announces Sale of Priority Review Voucher for USD105M

Liminal BioSciences Inc. (LMNL) doesn't possess the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.

Liminal BioSciences Inc. (LMNL) May Report Negative Earnings: Know the Trend Ahead of Q2 Release

LAVAL, QC and CAMBRIDGE, England, July 9, 2021 /PRNewswire/ - Liminal BioSciences Inc. (Nasdaq: LMNL) ("Liminal BioSciences" or the "Company"), a clinical-stage biopharmaceutical company, announced today that it has closed on the previously announced divestment of its plasma-derived therapeutics manufacturing subsidiary to Kedrion S.p.A. ("Kedrion") (the "First Closing").

Liminal BioSciences Announces Closing of Sale of Plasma-Derived Therapeutics Manufacturing Facility

LAVAL, QC and CAMBRIDGE, England, June 23, 2021 /PRNewswire/ - Liminal BioSciences Inc. (Nasdaq: LMNL) ("Liminal BioSciences" or the "Company"), announced today that, Kedrion S.p.A ("Kedrion") has exercised its option to acquire the remainder of the Company's plasma-derived business under the terms of the Share Purchase Agreement entered into by the Company and Kedrion. This acquisition would include the Ryplazim® (plasminogen, human-tvmh) ("Ryplazim®") business operated through its subsidiaries, Prometic Bioproduction Inc., the Company's plasma-derived therapeutics manufacturing facility ("PBP"), and Prometic Biotherapeutics Inc. ("PBT"), holder of the biological license application ("BLA") for Ryplazim® and associated Rare Pediatric Disease Priority Review Voucher ("PRV").

Liminal BioSciences Announces Signature of a Share Purchase Agreement for sale of Remaining Plasma-derived Business with Kedrion

The stock price of Liminal BioSciences Inc (NASDAQ: LMNL) increased by over 40% pre-market. This is why it happened.

LMNL Stock Price: Over 40% Increase Pre-Market Explanation

LAVAL, QC and CAMBRIDGE, England, June 4, 2021 /PRNewswire/ - Liminal BioSciences Inc. (Nasdaq: LMNL) ("Liminal BioSciences" or the "Company") announced the voting results from its Annual General and Special Meeting of Shareholders ("AGM") held virtually on June 4, 2021. A total of 22,136,650 common shares were voted, representing 73.93% of the votes attached to the issued and outstanding common shares of Liminal BioSciences.

Liminal Announces Voting Results of Its 2021 Annual and Special General Meeting of Shareholders (AGM)

LAVAL, QC and CAMBRIDGE, England, June 4, 2021 /PRNewswire/ - Liminal BioSciences Inc. (Nasdaq: LMNL) ("Liminal BioSciences" or the "Company") announced today that the U.S. Food & Drug Administration (FDA) has approved Ryplazim® (plasminogen, human-tvmh) ("Ryplazim®") for the treatment of patients with plasminogen deficiency type 1 (hypoplasminogenia) through its subsidiary, Prometic Biotherapeutics Inc., holder of the biological license application ("BLA") for Ryplazim®. With this approval, Ryplazim® becomes the first FDA approved therapy for this rare genetic disorder.

Liminal BioSciences Announces FDA Approval for its Biologics License Application for Ryplazim® (plasminogen, human-tvmh)

Based on interim pharmacokinetics (PK) results from the ongoing multiple ascending dose study Liminal BioSciences Inc (NASDAQ: LMNL) has decided not to move fezagepras into a Phase 2 study in Idiopathic Pulmonary Fibrosis and a Phase 1a/2b study in Hypertriglyceridemia. The Company is evaluating the interim PK results.

Liminal BioSciences Stock Falls on Scrapping Further Development of Fezagepras

LAVAL, QC and CAMBRIDGE, England, May 28, 2021 /PRNewswire/ - Liminal BioSciences Inc. (Nasdaq: LMNL) ("Liminal BioSciences" or the "Company"), a clinical-stage biopharmaceutical company, announced today that based on interim pharmacokinetic ("PK") results from the ongoing fezagepras multiple ascending dose (MAD) study, the Company has decided to stop its plans to move fezagepras into a Phase II clinical study in Idiopathic Pulmonary Fibrosis and a phase Ia/IIb study in Hypertriglyceridemia, as it evaluates the impact of the PK data profile observed in the on-going study. The Company is continuing to evaluate the interim PK results.

Liminal BioSciences Provides an Update on Currently Planned Clinical Activities for Fezagepras

LAVAL, QC and CAMBRIDGE, England, May 21, 2021 /PRNewswire/ - Liminal BioSciences Inc. (Nasdaq: LMNL) ("Liminal BioSciences" or the "Company"), a clinical-stage biopharmaceutical company, announced today that it has closed on the previously announced divestment of its 2 plasma collection centers, Prometic Plasma Resources Inc. and Prometic Plasma Resources (USA) Inc. (collectively, "PPRs") to Kedrion S.p.A. ("Kedrion").

Liminal BioSciences Announces Closing of Divestiture of Plasma Collection Centers and Enters into Option Agreement with Kedrion

Updated Business Strategy Focused on Small Molecule Therapeutics Kedrion to acquire, for a total of USD 17M, 2 plasma collection centers and an option to acquire the remaining plasma-derived therapeutic business for USD 5M Subject to Kedrion exercising said option, Liminal could receive up to 70% of net proceeds from sale of Priority Review Voucher for which it is potentially eligible with possible FDA approval for Ryplazim® PDUFA Target Action Date of June 5, 2021 for Ryplazim® (plasminogen) BLA Submission LAVAL, QC and CAMBRIDGE, England, May 17, 2021 /PRNewswire/ - Liminal BioSciences Inc. (Nasdaq: LMNL) ("Liminal BioSciences" or the "Company"), a clinical-stage biopharmaceutical company, today reported its financial results for the first quarter ended March 31, 2021. Liminal will host a conference call at 8:30 am (ET) on Tuesday May 18, 2021.

Liminal BioSciences Reports First Quarter 2021 Financial Results

Liminal BioSciences Inc (NASDAQ: LMNL) has agreed to sell its plasma collection and plasma-derived therapeutics business to Kedrion S.P.A. Under the Share Purchase Agreement, Liminal will enter into an option agreement with Kedrion for the right to acquire the remainder of the Company's plasma-derived business, and Prometic Biotherapeutics Inc, holder of the biological license application for Ryplazim (Plasminogen).

Liminal BioSciences To Offload Plasma Collection and Plasma-Derived Therapeutics Business To Kedrion

Kedrion to acquire, for a total of USD 17M, 2 plasma collection centers and an option to acquire the remaining plasma-derived therapeutic business for USD 5M Liminal to receive up to 70% of net proceeds from sale of Priority Review Voucher for which it is potentially eligible with possible FDA approval for Ryplazim® LAVAL, QC and CAMBRIDGE, England, May 17, 2021 /PRNewswire/ - Liminal BioSciences Inc. (Nasdaq: LMNL) ("Liminal BioSciences" or the "Company"), a clinical-stage biopharmaceutical company, announced today that the Company has signed a binding Share Purchase Agreement for the sale to Kedrion S.p.A. ("Kedrion") of its plasma collection centers operated in Winnipeg, Manitoba and Amherst, New York, through its subsidiaries, Prometic Plasma Resources Inc., and Prometic Plasma Resources (USA) Inc. The agreement reflects the recent announcement by Liminal BioSciences to focus its resources on the advancement of the Company's small molecule therapeutics business.

Liminal BioSciences Enters into Agreement with Kedrion to Divest Its Plasma Collection and Plasma-Derived Therapeutics Business

Liminal BioSciences Inc. (LMNL) May Report Negative Earnings: Know the Trend Ahead of Q1 Release

Liminal BioSciences, Inc. (LMNL) CEO Bruce Pritchard on Q4 2020 Results - Earnings Call Transcript

Liminal BioSciences Inc. (LMNL) delivered earnings and revenue surprises of -8.77% and 52.73%, respectively, for the quarter ended December 2020. Do the numbers hold clues to what lies ahead for the stock?

Liminal BioSciences Inc. (LMNL) Reports Q4 Loss, Tops Revenue Estimates

Initiated Phase 1 Multiple Ascending Dose Clinical Trial of Fezagepras OXER1 Antagonist Preclinical R&D Program Acquired Changes to Board of Directors & Executive Team US$30M in gross proceeds from a private placement closed in November C$29.1M in proceeds from long-term loan from SALP in September Updated Business Strategy Focused on Small Molecule Therapeutics PDUFA Target Action Date of June 5, 2021 for Ryplazim® (plasminogen) BLA Submission LAVAL, QC and CAMBRIDGE, England, March 24, 2021 /PRNewswire/ - Liminal BioSciences Inc. (Nasdaq: LMNL) ("Liminal BioSciences" or the "Company"), a clinical-stage biopharmaceutical company, today reported its financial results for the fourth quarter and year ended December 31, 2020. Liminal will host a conference call at 08:30am (ET) on Thursday March 25, 2021.

Liminal BioSciences Reports Fourth Quarter and Year End 2020 Financial Results

Liminal BioSciences Inc. (LMNL) May Report Negative Earnings: Know the Trend Ahead of Q4 Release

BJ`s Wholesale Club Holdings Inc

Bellicum Pharmaceuticals

360 Finance Inc - ADR

Vaccinex Inc

Meridian Bioscience

Want to try some out-of-the-box approach? Tap five stocks with increasing P/E ratios.

News for Liminal BioSciences Stock (LMNL)